Bright Minds Biosciences to present at upcoming conferences
Bright Minds Biosciences, Inc. says it will present at upcoming conferences. The company focuses on developing highly selective 5-HT2 agonists for drug-resistant epilepsy, Prader-Willi Syndrome, depression and other indications.
NEW YORK, Sept.
04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) NASDAQ:DRUG, a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other cen…